Literature DB >> 15070686

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.

Michael R Verneris1, Mobin Karimi, Mobin Karami, Jeanette Baker, Anishka Jayaswal, Robert S Negrin.   

Abstract

Activating and expanding T cells using T-cell receptor (TCR) cross-linking antibodies and interleukin 2 (IL-2) results in potent cytotoxic effector cells capable of recognizing a broad range of malignant cell targets, including autologous leukemic cells. The mechanism of target cell recognition has previously been unknown. Recent studies show that ligation of NKG2D on natural killer (NK) cells directly induces cytotoxicity, whereas on T cells it costimulates TCR signaling. Here we demonstrate that NKG2D expression is up-regulated upon activation and expansion of human CD8+ T cells. Antibody blocking, redirected cytolysis, and small interfering RNA (siRNA) studies using purified CD8+ T cells demonstrate that cytotoxicity against malignant target cells occurs through NKG2D-mediated recognition and signaling and not through the TCR. Activated and expanded CD8+ T cells develop cytotoxicity after 10 to 14 days of culture, coincident with the expression of the adapter protein DAP10. T cells activated and expanded in low (30 U/mL) and high (300 U/mL) concentrations of IL-2 both up-regulated NKG2D expression equally, but only cells cultured in high-dose IL-2 expressed DAP10 and were cytotoxic. Collectively these results establish that NKG2D triggering accounts for the majority of major histocompatibility complex (MHC)-unrestricted cytotoxicity of activated and expanded CD8+ T cells, likely through DAP10-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070686     DOI: 10.1182/blood-2003-06-2125

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  142 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

3.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Authors:  Abel Torres; Leslie Storey; Makala Anders; Richard L Miller; Barbara J Bulbulian; Jizhong Jin; Shalini Raghavan; James Lee; Herbert B Slade; Woubalem Birmachu
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

5.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

6.  A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.

Authors:  Weng-Chee Chan; Yeh-Ching Linn
Journal:  Cytotechnology       Date:  2014-12-07       Impact factor: 2.058

7.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

8.  Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).

Authors:  Sung Hee Yoon; Jin Myung Lee; Sun-Je Woo; Min-Ji Park; Jung-Sun Park; Hye-Sung Kim; Mi-Young Park; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  J Clin Immunol       Date:  2009-06-11       Impact factor: 8.317

9.  Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Authors:  Richard K Yang; Nicholas A Kalogriopoulos; Alexander L Rakhmilevich; Erik A Ranheim; Songwon Seo; Kyungmann Kim; Kory L Alderson; Jacek Gan; Ralph A Reisfeld; Stephen D Gillies; Jacquelyn A Hank; Paul M Sondel
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

10.  A truncated human NKG2D splice isoform negatively regulates NKG2D-mediated function.

Authors:  Cynthia L Baldwin; Taku Kambayashi; Mobin A Karimi; Oscar Aguilar; Baixiang Zou; Michael H Bachmann; James R Carlyle
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.